230 related articles for article (PubMed ID: 23993306)
1. A simple quantitative diagnostic alternative for MGMT DNA-methylation testing on RCL2 fixed paraffin embedded tumors using restriction coupled qPCR.
Pulverer W; Hofner M; Preusser M; Dirnberger E; Hainfellner JA; Weinhaeusel A
Clin Neuropathol; 2014; 33(1):50-60. PubMed ID: 23993306
[TBL] [Abstract][Full Text] [Related]
2. Confounding factors in diagnostics of MGMT promoter methylation status in glioblastomas in stereotactic biopsies.
Weise LM; Harter PN; Eibach S; Braczynski AK; Dunst M; Rieger J; Bähr O; Hattingen E; Steinbach JP; Plate KH; Seifert V; Mittelbronn M
Stereotact Funct Neurosurg; 2014; 92(3):129-39. PubMed ID: 24776650
[TBL] [Abstract][Full Text] [Related]
3. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
Drabycz S; Roldán G; de Robles P; Adler D; McIntyre JB; Magliocco AM; Cairncross JG; Mitchell JR
Neuroimage; 2010 Jan; 49(2):1398-405. PubMed ID: 19796694
[TBL] [Abstract][Full Text] [Related]
4. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis.
Mikeska T; Bock C; El-Maarri O; Hübner A; Ehrentraut D; Schramm J; Felsberg J; Kahl P; Büttner R; Pietsch T; Waha A
J Mol Diagn; 2007 Jul; 9(3):368-81. PubMed ID: 17591937
[TBL] [Abstract][Full Text] [Related]
5. Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens.
Preusser M; Elezi L; Hainfellner JA
Clin Neuropathol; 2008; 27(6):388-90. PubMed ID: 19130735
[TBL] [Abstract][Full Text] [Related]
6. Clinical Neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma.
Preusser M; Berghoff AS; Manzl C; Filipits M; Weinhäusel A; Pulverer W; Dieckmann K; Widhalm G; Wöhrer A; Knosp E; Marosi C; Hainfellner JA
Clin Neuropathol; 2014; 33(1):6-14. PubMed ID: 24359605
[TBL] [Abstract][Full Text] [Related]
7. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients.
Lakomy R; Sana J; Hankeova S; Fadrus P; Kren L; Lzicarova E; Svoboda M; Dolezelova H; Smrcka M; Vyzula R; Michalek J; Hajduch M; Slaby O
Cancer Sci; 2011 Dec; 102(12):2186-90. PubMed ID: 21895872
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
[TBL] [Abstract][Full Text] [Related]
9. Determination of the methylation status of MGMT in different regions within glioblastoma multiforme.
Hamilton MG; Roldán G; Magliocco A; McIntyre JB; Parney I; Easaw JC
J Neurooncol; 2011 Apr; 102(2):255-60. PubMed ID: 20652362
[TBL] [Abstract][Full Text] [Related]
10. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
[TBL] [Abstract][Full Text] [Related]
11. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.
Xie H; Tubbs R; Yang B
Int J Clin Exp Pathol; 2015; 8(2):1790-6. PubMed ID: 25973069
[TBL] [Abstract][Full Text] [Related]
12. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
[TBL] [Abstract][Full Text] [Related]
13. MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens.
Lattanzio L; Borgognone M; Mocellini C; Giordano F; Favata E; Fasano G; Vivenza D; Monteverde M; Tonissi F; Ghiglia A; Fillini C; Bernucci C; Merlano M; Lo Nigro C
Int J Biol Markers; 2015 May; 30(2):e208-16. PubMed ID: 25588856
[TBL] [Abstract][Full Text] [Related]
14. Fixation of brain tumor biopsy specimens with RCL2 results in well-preserved histomorphology, immunohistochemistry and nucleic acids.
Preusser M; Plumer S; Dirnberger E; Hainfellner JA; Mannhalter C
Brain Pathol; 2010 Nov; 20(6):1010-20. PubMed ID: 20477829
[TBL] [Abstract][Full Text] [Related]
15. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.
Xie H; Tubbs R; Yang B
Int J Clin Exp Pathol; 2015; 8(1):636-42. PubMed ID: 25755756
[TBL] [Abstract][Full Text] [Related]
16. MethylMeter(®): bisulfite-free quantitative and sensitive DNA methylation profiling and mutation detection in FFPE samples.
McCarthy D; Pulverer W; Weinhaeusel A; Diago OR; Hogan DJ; Ostertag D; Hanna MM
Epigenomics; 2016 Jun; 8(6):747-65. PubMed ID: 27337298
[TBL] [Abstract][Full Text] [Related]
17. MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?
Della Puppa A; Persano L; Masi G; Rampazzo E; Sinigaglia A; Pistollato F; Denaro L; Barzon L; Palù G; Basso G; Scienza R; d'Avella D
J Neurooncol; 2012 Jan; 106(1):33-41. PubMed ID: 21725802
[TBL] [Abstract][Full Text] [Related]
18. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
[TBL] [Abstract][Full Text] [Related]
19. Learning MRI-based classification models for MGMT methylation status prediction in glioblastoma.
Kanas VG; Zacharaki EI; Thomas GA; Zinn PO; Megalooikonomou V; Colen RR
Comput Methods Programs Biomed; 2017 Mar; 140():249-257. PubMed ID: 28254081
[TBL] [Abstract][Full Text] [Related]
20. Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.
Quillien V; Lavenu A; Ducray F; Joly MO; Chinot O; Fina F; Sanson M; Carpentier C; Karayan-Tapon L; Rivet P; Entz-Werle N; Legrain M; Zalcman EL; Levallet G; Escande F; Ramirez C; Chiforeanu D; Vauleon E; Figarella-Branger D
Oncotarget; 2016 Sep; 7(38):61916-61929. PubMed ID: 27542245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
